Novatek Pharma initiates Phase II study of oral COVID-19 drug
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
The goal for the project is the identification and optimization of anti-viral compounds.
This robust growth has come despite the raging pandemic for most part of the quarter
In the agreement, Marcor, an Azelis Americas company, will distribute the SPI Pharma product lines in the United States, and Azelis Canada Pharma Division will be responsible for the Canadian marketplace
It had an estimated market size of US $ 32 million as of June 2021
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
Subscribe To Our Newsletter & Stay Updated